116 related articles for article (PubMed ID: 20554943)
1. Tamoxifen and the factor V Leiden mutation.
Cuzick J
J Natl Cancer Inst; 2010 Jul; 102(13):918-9. PubMed ID: 20554943
[No Abstract] [Full Text] [Related]
2. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
Garber JE; Halabi S; Tolaney SM; Kaplan E; Archer L; Atkins JN; Edge S; Shapiro CL; Dressler L; Paskett ED; Kimmick G; Orcutt J; Scalzo A; Winer E; Levine E; Shahab N; Berliner N;
J Natl Cancer Inst; 2010 Jul; 102(13):942-9. PubMed ID: 20554945
[TBL] [Abstract][Full Text] [Related]
3. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
4. Caring for the breast cancer survivor.
Abdel-Razeq H
Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
[No Abstract] [Full Text] [Related]
5. Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and the risk of tamoxifen-associated thromboembolism in breast cancer patients.
Eroğlu A; Akar N
Thromb Res; 2011 Apr; 127(4):384-5. PubMed ID: 21093891
[No Abstract] [Full Text] [Related]
6. Tamoxifen side effects may be attributable to other causes.
Jones J
J Natl Cancer Inst; 2001 Jan; 93(1):11-2. PubMed ID: 11136833
[No Abstract] [Full Text] [Related]
7. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
Weitz IC; Israel VK; Liebman HA
Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen-related vasculitis.
Baptista MZ; Prieto VG; Chon S; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Jul; 24(21):3504-5. PubMed ID: 16849770
[No Abstract] [Full Text] [Related]
11. New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer.
Rosenberg SM; Partridge AH
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307642
[No Abstract] [Full Text] [Related]
12. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
14. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen: an enduring star.
Veronesi U; Maisonneuve P; Decensi A
J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
[No Abstract] [Full Text] [Related]
16. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?
Trinkaus M; Chin S; Wolfman W; Simmons C; Clemons M
Oncologist; 2008 Mar; 13(3):222-31. PubMed ID: 18378532
[TBL] [Abstract][Full Text] [Related]
17. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.
McCaskill-Stevens W; Wilson J; Bryant J; Mamounas E; Garvey L; James J; Cronin W; Wickerham DL
J Natl Cancer Inst; 2004 Dec; 96(23):1762-9. PubMed ID: 15572758
[TBL] [Abstract][Full Text] [Related]
18. Hormonal treatment duration in elderly patients: an open question.
Crivellari D; Goldhirsch A; Coates A
J Clin Oncol; 2004 Mar; 22(6):1164-5; author reply 1165. PubMed ID: 15020626
[No Abstract] [Full Text] [Related]
19. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
Vastag B
J Natl Cancer Inst; 2006 Jun; 98(11):733-5. PubMed ID: 16757696
[No Abstract] [Full Text] [Related]
20. Chemoprevention of breast cancer: recommendations and rationale.
Berg AO;
Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
